Mr. Christopher Moreau reports

ALGERNON HEALTH ANNOUNCES NOVASCAN NEUROIMAGING CLINICS™ AS THE NEW BRAND NAME FOR ITS U.S. BRAIN PET SCANNING CENTERS

Algernon Health Inc. has introduced NovaScan Neuroimaging Clinics as the new brand name and visual identity for its planned United States network of brain PET scanning centres being launched at the HCA Florida University Medical Offices building in Davie, and featuring the United States' Food and Drug Administration-cleared CareMiBrain system, a groundbreaking, stand-alone PET scanner without an integrated CT component.

The new brand name and visual identity has been designed with a clean and elegant look reflective of the company's vision for a streamlined approach to dedicated brain PET imaging, and the revolutionary technology that the company clinics will feature.

The name incorporates the words "Nova" and "Scan," the former of which is a Latin derivative meaning "new." Together, they combine to form an original name capturing the spirit of the next chapter in medical imaging to be anchored in optimized scanning, highest-quality reporting, rapid turnarounds and a high-touch, comfort enhanced patient experience.

The navy and red fonts offer a strong element of American heritage while the logo, comprising an offset collection of two groupings of circles has been designed to reflect the shape of a brain and its stem. The circles represent the aspiration of cognitive health and harmony for all patients while the various colours -- blue, purple, green, pink and grey -- evoke additional sentiments of trust, insight, renewal, compassion and balance in the delivery of the company's medical services.

The Florida clinic will be the first of its kind in the U.S. providing dedicated, brain optimized PET scans to aid in the detection and treatment of Alzheimer's disease, by confirming the presence of beta-amyloid plaques associated with Alzheimer's progression. The clinic will also scan patients for other forms of dementia, epilepsy, Parkinson's disease, multiple sclerosis and brain cancer, and will also be available for use in clinical trials to help test new tracers being developed.

Because The CareMiBrain technology is a stand-alone system and is not combined with computed tomography (CT), patients receive 25-per-cent less radiation. With traditional PET/CT scanners, the CT component cannot be turned off during a brain scan because the data and images are interwoven.

"Our goal was to settle on a name and symbol that would capture the essence of what we are planning to achieve in offering a new approach to dedicated brain PET scanning as an important component of the healthcare system," says Christopher J. Moreau, chief executive officer of Algernon Health. "We will quite literally be offering a 'new scan' and experience through our clinics and an advanced standard of technology and service to patients and the medical community alike."

The company's inaugural clinic at the HCA Florida University Medical Offices building in Davie is approximately 20 minutes southwest of Fort Lauderdale.

Algernon will provide an update shortly on its planned official clinic opening date and when it will be able to start accepting referrals and begin conducting PET brain scans for patients.

About Algernon Health Inc.

Algernon is a Canadian health care company focused on the provision of brain specific PET scanning services through a planned network of new neuroimaging clinics in the U.S. for the early stage detection of Alzheimer's disease, and other forms of dementia, as well as epilepsy, neuro-oncology and movement disorders, including Parkinson's disease. Algernon has a program for Repirinast, a repurposed drug for CKD, and is also the parent company of Algernon NeuroScience, a wholly owned subsidiary, that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The company's chronic cough drug Ifenprodil, which works by stopping cough in the brain, was sold for $2-million (U.S.) cash and a 20-per-cent equity position in Seyltx, a private U.S.-based drug development company that continues to advance research on the drug.

We seek Safe Harbor.